Alta Sciences

APRIL 8, 2025

Precedence Research reports that the global ophthalmic drug market size is estimated to double in 10 years, from $34.6 billion by 2030. The development of pharmacological interventions for many of these conditions has been accelerating, supported by new delivery methods and formulation approaches.

Clinical Trials 52

Clinical Trials Nurses Trials Compliance 52

The Pharma Data

FEBRUARY 21, 2022

We are taking bold steps into the future of drug development, investing strongly in areas at the forefront of the biomedical and technological revolution. Our scientific leadership in the area of cardiovascular diseases advances our mission to provide better treatment options for patients in need.”.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

DrugBank

FEBRUARY 19, 2025

The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

Vial

APRIL 18, 2024

Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. from 2023 to 2030. Additionally, the ophthalmic drugs market, valued at USD 33.81 Additionally, the ophthalmic drugs market, valued at USD 33.81

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

Perficient: Drug Development

AUGUST 8, 2023

By 2030, the last of the 73 million baby boomers will cross the threshold into Medicare eligibility. Many of us have a somewhat dated view of the 65-plus population, but these folks aren’t your grandma’s grandma. Boomers may have grown up in an analog-world, but they have been steadily riding the technology wave ever since.

Production 52

Production Treatment Marketing Research 52

Vial

FEBRUARY 15, 2024

over the forecast period (2022-2030). Factors such as patient access and safety, infrastructure, site experience in clinical research, trial phase requirements, suitability for treatment, and ethical concerns must be carefully considered during site selection3,4.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

Vial

MARCH 27, 2024

The Costs of Working with a CRO Running clinical trials is an integral part of the pharmaceutical industry, crucial to the development and approval of new drugs and treatments. from 2024 to 2030. According to a report by Grand View Research, the global CRO services market was valued at approximately US$50.55

Clinical Trials 52

Clinical Trials Trials International Compliance 52

DrugBank

AUGUST 9, 2024

This high attrition rate directly results from the scientific and regulatory hurdles that drug candidates must overcome. The Investment Landscape Despite these challenges, the potential rewards for successful drug development are substantial. The market for cardiovascular drugs, valued at 155.6 billion by 2030.

Pharmaceuticals 99

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 99

The Pharma Data

NOVEMBER 5, 2020

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” ” “We continue to invest in our promising pipeline while delivering meaningful revenue and earnings growth.

Production 40

Production FDA Trials FDA Approval 40

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  While the demand for novel antibiotics is undeniable, the industry still struggles with the harsh realities of antibiotic drug development. This costly, high-risk development pipeline has high attrition rates and uncertain market returns.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Government DNA 98

NIH Director's Blog: Drug Development

MAY 15, 2018

Fortunately, the drug available to me then was effective, but I was pretty sick for a few days. Since that time, malarial drug resistance has become steadily more widespread. In fact, the treatment that cured me would be of little use today. References: [1] Overview of malaria treatment. World Health Organization.

Drug Development 52

Drug Development Drugs Disease Treatment 52

PPD

JANUARY 21, 2025

However, amid this progress, the complexities of drug development have never been more apparent. Food and Drug Administration (FDA) approved 38 new molecular entities for therapeutic use, a decline from 47 in the previous year. In 2024, the U.S. The data revealed five key trends poised to shape biopharma and biotech in 2025.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52